Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS oncogene in lung cancer: focus on molecularly driven clinical trials.

European respiratory review : an official journal of the European Respiratory Society - 1 Mar 2016

Kempf Emmanuelle, Rousseau Benoît, Besse Benjamin, Paz-Ares Luis

Abstract excerpt

KRAS mutations are the most frequent molecular abnormalities found in one out of four nonsmall cell lung cancers (NSCLC). Their incidence increases in cases of adenocarcinoma, smokers and Caucasian patients. Their negative value in terms of prognosis and responsiveness to both standard chemotherapy and targeted therapies remains under debate. Many drugs have been developed specifically for KRAS-mutated NSCLC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Molecular Diagnostic Techniques

Share to Molecular Targeted Therapy

Share to Precision Medicine

Share to Predictive Value of Tests

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 26929424
DOI: 10.1183/16000617.0071-2015
PMCID: PMC9487658

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS oncogene in lung cancer: focus on molecularly driven clinical trials.PMID 26929424Read ↗

Treating KRAS -mutant NSCLC: latest evidence and clinical consequencesSemantic proximity Read ↗

KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives.Semantic proximity Read ↗

KRAS mutant lung cancer: progress thus far on an elusive therapeutic targetSemantic proximity Read ↗

Targeting KRAS mutant lung cancer: light at the end of the tunnel.Semantic proximity Read ↗

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.Semantic proximity Read ↗

Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review.Semantic proximity Read ↗

An Updated Review on KRAS Mutation in Lung Cancer (NSCLC) and Its Effects on Human Health.Semantic proximity Read ↗

KRAS mutations in lung cancer.Semantic proximity Read ↗

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibitionSemantic proximity Read ↗

KRAS-Mutant non-small cell lung cancer: From biology to therapySemantic proximity Read ↗

[Therapeutic possibilities in KRAS-mutant lung adenocarcinoma].Semantic proximity Read ↗

[KRAS and bronchial adenocarcinoma. Between disappointments and hopes].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.